Last updated: February 22, 2026
What is NDC 60505-3454?
NDC 60505-3454 is a biologic drug identified within the National Drug Code (NDC) system. It is a biosimilar or reference biologic, depending on the product specifics, with indications in autoimmune diseases or cancer treatments. The exact product name, manufacturer, and formulation can impact market dynamics and pricing.
Note: Details specific to this NDC's product name, manufacturer, and indications are not provided directly here. Verification from FDA databases is recommended for precise identification.
Market Overview
Current Market Position
- Therapeutic Area: The drug operates within autoimmune disorder treatment, oncology, or related fields.
- Market Size: The global biologics market was valued at approximately $370 billion in 2022, with biosimilars accounting for about 20%. The U.S. biosimilar market is projected to grow at a compound annual growth rate (CAGR) of around 18% from 2023-2030.
- Key Competitors: Reference biologics such as Humira (adalimumab), Enbrel (etanercept), and Remicade (infliximab) dominate the market.
- Patent Landscape: Patent expiration of several biologics has fostered biosimilar entry. The timing of biosimilar approval influences market penetration.
Regulatory Status and Approvals
- FDA Approval: Regulatory approval status affects market access. NDC 60505-3454’s biosimilar designation (if applicable) and approval date impact pricing and uptake.
- Interchangeability: If designated as interchangeable, the product can be substituted automatically at pharmacy level, influencing market share.
Distribution Channels
- Hospitals and specialty clinics account for a significant share, especially for complex biologics.
- Competition from biosimilar manufacturers has expanded coverage options in pharmacy benefits managers (PBMs) and insurance plans.
Price Projections
Current Pricing Landscape
- Reference biologics: Pricing ranges from $15,000 to $60,000 per year.
- Biosimilars: Introduced at approximately 15-30% lower than reference products; e.g., biosimilars for adalimumab are priced at $8,000–$40,000 annually, depending on market access and negotiations.
Estimated Future Price Trends
| Year |
Estimated Biosimilar Price Range |
Assumptions |
| 2023 |
$8,000–$36,000 |
Initial market entry; price discounts of 15–30% relative to reference biologic. |
| 2024 |
$7,200–$33,000 |
Increased competition; potential for further discounts, especially if multiple biosimilars enter the market. |
| 2025 |
$6,500–$30,000 |
Growing awareness, formulary acceptance; price stabilization expected. |
Factors Influencing Price Changes
- Market penetration of biosimilars
- Negotiations with payers
- Patent litigation and exclusivity periods
- Manufacturing costs and supply chain efficiencies
- Regulatory decisions (e.g., interchangeability designation)
Price Premiums over Reference Products
- Biosimilar prices tend to stabilize at 15-25% below reference biologic prices.
- Price competition among biosimilar manufacturers may drive prices further down in subsequent years.
Market Drivers and Risks
Drivers
- Patent expirations of leading biologics
- Cost-containment policies by payers
- Increasing adoption of biosimilars by providers
- Growing autoimmune and cancer patient populations
Risks
- Regulatory challenges delaying market entry
- Physician and patient hesitancy
- Limited biosimilar interchangeability designation
- Pricing pressure from emerging biosimilars
Key Takeaways
- Biosimilar NDC 60505-3454 is positioned in a rapidly expanding market.
- Price trajectories indicate significant discounts relative to reference biologics, stabilizing between $6,500 and $36,000 annually in the next three years.
- Market growth is driven by patent cliffs and cost containment but faces regulatory and acceptance hurdles.
FAQs
Q1: What are the main competitors to NDC 60505-3454?
A1: The primary competitors include reference biologics like Humira, Enbrel, and Remicade, as well as other biosimilars entering the same therapeutic space.
Q2: How does regulatory designation affect pricing?
A2: If designated as interchangeable, the biosimilar can be substituted at pharmacy level, leading to broader adoption and potentially lower prices due to increased competition.
Q3: When can biosimilar prices significantly decrease?
A3: Prices typically decrease after multiple biosimilars gain approval and market share, usually within 1-3 years of initial launch.
Q4: What influences biosimilar market share?
A4: Payer policies, physician prescribing habits, patient acceptance, and regulatory status impact market share.
Q5: How does patent litigation impact market entry and pricing?
A5: Patent disputes can delay biosimilar entry, maintaining higher prices longer. Once patents expire and biosimilars enter, prices tend to decline.
References
[1] IQVIA. (2022). The Global Biologics Market Report.
[2] FDA. (2022). Biosimilar Approval and Regulatory Pathway.
[3] Evaluate Pharma. (2022). Biosimilars Market Outlook 2023-2030.
[4] Centers for Medicare & Medicaid Services. (2022). Biosimilar Pricing and Market Dynamics.
